Amaero (3DA) IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 summary
Event summary combining transcript, slides, and related documents.
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 summary
23 Jun, 2026Strategic positioning and market overview
Largest U.S. producer of refractory and titanium alloy powders for 3D printing in defense, aerospace, space, and nuclear sectors.
Relocated headquarters from Australia to the U.S. in July 2023, now a Delaware company, maintaining ASX listing.
Completed a three-year, $50 million capital investment, building a 100,000 sq ft facility in Tennessee with advanced atomization and PM-HIP capabilities.
Positioned at the intersection of defense industrial base, reshoring manufacturing, and critical minerals trends.
Only one or two competitors in each business segment, addressing key supply chain bottlenecks.
Technology and operational advantages
Proprietary modifications to IGA Premium gas atomization technology yield higher output and lower costs.
Uses half the argon gas compared to competitors and benefits from subsidized electricity in Tennessee.
PM-HIP technology offers immediate substitution for large forgings and castings, critical for defense and naval applications.
Dedicated atomizer for refractory alloys, addressing long lead times and supply constraints.
Focus exclusively on high-value, supply-constrained spherical reactive metals market.
Growth drivers and financial outlook
First full year of revenue expected at AUD 18–20 million, with strong growth visibility for subsequent years.
Business could grow 75% year-over-year for several years, driven by secured contracts and robust demand.
About 75% of next year's plan already contracted, with strong demand in both refractory (government) and titanium (commercial) segments.
Revenue potential scales to $200 million, with further expansion opportunities through regional manufacturing hubs.
Pursuing a U.S. IPO late 2026 or early 2027, pending market conditions.
Latest events from Amaero
- Record revenue growth, strong backlog, and U.S. IPO plans mark a pivotal year.3DA
Q4 2026 TU - Shareholders and option holders strongly approved all proposed schemes and director option grants.3DA
Scheme Meeting 2026 presentation - Q3 FY2026 revenue up 301%–347% YoY, FY2026 fully contracted, U.S. redomiciliation advances.3DA
Q3 2026 TU - FY2025 saw record revenue, major supply deals, and facility expansion, setting up strong FY2026 growth.3DA
H2 2025 - Strategic U.S. shift, capital raises, and C103 supply deals set path to EBITDA breakeven by FY2026.3DA
H2 2024 - Revenue up 367%, net loss widens, FY2026 guidance cut amid U.S. contract delays.3DA
H1 2026 - Production and revenue scale rapidly with new atomizer, strong contracts, and U.S. market demand.3DA
Status Update - Transition to commercialization, capital raises, and U.S. expansion with new leadership.3DA
AGM 2024 - Seven resolutions, including share placements and a name change, were presented and voted online.3DA
EGM 2025